Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
AbbVie and Shire agree on a $54 billion merger deal, with AbbVie paying about $54 billion in cash and stock to Shires shareholders in a tax inversion…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
AbbVie agreed to acquire Shire in a $54 billion deal that would have moved AbbVie's tax domicile to Ireland. AbbVie terminated the deal in October 2014 after the US Treasury tightened tax inversion rules, paying Shire a $1.635 billion breakup fee.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AbbVie Inc. / Shire plc (this deal) | 2014 | $54.0B | 30 |
| AbbVie Inc. / Boehringer Ingelheim GmbH | 2016 | $2.2B | 95 |
| AbbVie Inc. / Genmab A/S | 2020 | $3.9B | 81 |
| AbbVie Inc. / Pharmacyclics Inc. | 2015 | $21.0B | 79 |
| AbbVie Inc. / Apogee Therapeutics, Inc. | 2026 | $10.9B | 72 |
| AbbVie Inc. / ImmunoGen Inc. | 2023 | $10.1B | 69 |
| AbbVie Inc. / Gilgamesh Pharmaceuticals Inc. | 2024 | $2.0B | 64 |
← Browse all deals · How we score deals
More: 2014 deals · AbbVie Inc. deals · Immunology deals